Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
24 April, 2018 06:41 IST
Zydus Cadila gets Mexican regulatory authority's nod for Lipaglyn
Source: IRIS | 13 Nov, 2017, 11.41AM
Comments  |  Post Comment

Zydus announced that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval to commercialize Lipaglyn™ (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.
 
Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).
 
''Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia,'' said Pankaj Patel, Chairman, Zydus Group, and added, ''This approval of Saroglitazar in Mexico is a major milestone for the company.''

Shares of the company declined Rs 27.65, or 5.78%, to trade at Rs 451.00. The total volume of shares traded was 51,256 at the BSE (11.17 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Bharti Infratel quarterly profit climbs 1.58% - 23-Apr-2018 18:10
US sanctions on RUSAL put Indian automobile industry on crossfire: ICRA - 23-Apr-2018 17:24
Petrol price touches Rs 74.40, diesel at record high of Rs 65.65 - 23-Apr-2018 13:42
Mahindra Powerol launches new range of high power diesel generators - 23-Apr-2018 13:36
Salasar Techno Engg secures orders worth Rs 490 mn - 23-Apr-2018 13:02
Gujarat Ambuja Exports completes 1st phase of greenfield maize processing plant - 23-Apr-2018 12:58
Lupin receives USFDA for generic of Xenazine tablets - 23-Apr-2018 12:52
Indian Hume Pipe surges after new order win - 23-Apr-2018 12:47
Shilpa Medicare rises post EU-GMP approval for three plants - 23-Apr-2018 12:39
Indian Overseas Bank signs agreement with NeSL - 23-Apr-2018 10:21
HDFC Bank Q4 net grows 20% to Rs 47.99 bn - 23-Apr-2018 10:17
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer